Investigating blood markers in juvenile idiopathic arthritis
Official title: Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Run by Assistance Publique - Hôpitaux de Paris · NCT05534347 · Data updated 2026-11-12
This study is testing if certain blood markers can help predict how severe juvenile idiopathic arthritis will be in young patients as they move from pediatric to adult care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, IDF) |
| Status | Recruiting |
| Started | March 13, 2023 |
| Main results expected | March 2030 |
| Study ends | March 2030 |
| Registry record updated | September 12, 2025 |
| Trial ID | NCT05534347 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 16 and older diagnosed with juvenile idiopathic arthritis who are receiving specialized follow-up in rheumatology.
✕Probably not a fit
Patients under curatorship or guardianship, or those receiving French state medical aid, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate whether serum inflammatory angiogenic markers, such as semaphorins and CCN1, can predict the severity of juvenile idiopathic arthritis (JIA) by assessing structural progression and therapeutic escalation. The research focuses on patients transitioning from pediatric to adult care, examining the relationship between these biomarkers and disease severity. By analyzing blood samples and joint punctures, the study seeks to establish predictive parameters for JIA severity, similar to findings in rheumatoid arthritis.
Why it matters
Potential benefit: If successful, this study could provide a new method for predicting disease severity in juvenile idiopathic arthritis, leading to better management and treatment strategies.
How similar studies have gone: Previous studies have shown success in using angiogenic biomarkers to predict severity in rheumatoid arthritis, suggesting potential applicability in juvenile idiopathic arthritis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Greater than or equal to 16 years-old * Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital * No-opposition to the research * Patient with health insurance * Mastery of the French language Exclusion Criteria: * Patient under curatorship or guardianship * Patient receiving french state medical aid
Where it's running
-
Rheumatology Department, Cochin Hospital
Paris, Idf, France Recruiting
Study contacts
- Principal investigator: Yannick ALLANORE, PD, PhD — Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
- Study coordinator: Yannick ALLANORE, PD, PhD
- Email: yannick.allanore@aphp.fr
- Phone: 0033158412563
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting the course of early-onset juvenile idiopathic arthritis using a multidimensional model
Researchers are testing a comprehensive model to predict how early-onset JIA will progress in affected children and how a small control group with iridocyclitis compares.
-
Understanding subtypes of chronic musculoskeletal pain in youth
This observational study tests whether distinct brain and immune profiles can explain chronic musculoskeletal pain in teens and young adults to guide more precise treatments.
-
Open-label extension with filgotinib for juvenile idiopathic arthritis
This long-term open-label extension sees if filgotinib stays safe and continues to control symptoms in children aged 8–17 with polyarticular or systemic juvenile idiopathic arthritis who benefited from earlier treatment.
-
Structured or video-game–based core stabilization for children with juvenile idiopathic arthritis
This study will try whether a regular structured core exercise program or a fun exergaming-based core program helps children aged 8–13 with juvenile idiopathic arthritis improve strength, reduce pain, and move better.
-
Tofacitinib in Juvenile Idiopathic Arthritis
This study looks at real-world use of tofacitinib to see if it helps control Juvenile Idiopathic Arthritis in kids over about 12 months.
-
Parents' pain catastrophizing in children with juvenile idiopathic arthritis
See if parents' worrying and negative thoughts about their child's pain are linked to treatment adherence and biopsychosocial outcomes in children with juvenile idiopathic arthritis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.